DJIA 17,678.70 6.10 0.03%
NASDAQ 4,771.76 13.88 0.29%
S&P 500 2,057.09 5.27 0.26%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)



company name or ticker

Alnylam Reports Positive Initial Phase II Data on Revusiran - Analyst Blog

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog

Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog

Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepat

Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus Infection And ALN-PDL For The Treatment Of Chronic Liver Infections

Isis Pharmaceuticals Inc. Strikes Out on Its Own

Isis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.

Alnylam Pharmaceuticals Staying Ridiculously Busy

Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog

Investing in Socially Responsible Companies: Alnylam Pharmaceuticals, Inc.

Some socially responsible companies are very strong performers.

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2014 Results - Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. Has This Ratio Right

Alnylam's third-quarter earnings call was all about the pipeline data.
See More Articles...